ME

23Andme Holding Co
NASDAQ
1.790
+0.030
+1.70%
After Hours: 1.820 +0.03 +1.68% 19:57 03/21 EDT
OPEN
1.750
PREV CLOSE
1.760
HIGH
1.830
LOW
1.710
VOLUME
205.51K
TURNOVER
--
52 WEEK HIGH
12.76
52 WEEK LOW
1.340
MARKET CAP
48.02M
P/E (TTM)
-0.1159
1D
5D
1M
3M
1Y
5Y
1D
23andMe launches new homocysteine genetic report, lab test
TipRanks · 2d ago
23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
Barchart · 2d ago
ZENTREE INVESTMENTS - SEEK TO PREVENT SALE OF 23ANDME AT UNREASONABLE PRICE, ADVOCATE FOR MORE PRUDENT MANAGEMENT OF COSTS
Reuters · 6d ago
ZENTREE INVESTMENTS LIMITED REPORTS 13.0% STAKE IN 23ANDME HOLDING CO AS OF MARCH 12 - SEC FILING
Reuters · 6d ago
Weekly Report: what happened at ME last week (0310-0314)?
Weekly Report · 6d ago
23andMe gains after CEO Wojcicki makes revised $2.94/share offer with CVR
Seeking Alpha · 03/10 15:08
Weekly Report: what happened at ME last week (0303-0307)?
Weekly Report · 03/10 09:25
Wall Street Breakfast Podcast: Tariff Hit Sends Auto Stocks Sliding
Seeking Alpha · 03/04 11:45
More
About ME
23andMe Holding Co. is a genetics-led consumer healthcare and biopharmaceutical company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Webull offers 23andMe Holding Co. stock information, including NASDAQ: ME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ME stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ME stock methods without spending real money on the virtual paper trading platform.